Evidence map›Paper›PMID 40646002›Full record

ArticleNature communications2025

Host albumin redirects Candida albicans metabolism to engage an alternative pathogenicity pathway.

Sophia U J Hitzler, Candela Fernández-Fernández, Kerstin Günther, Axel Dietschmann, Hrant Hovhannisyan, Anna Möslinger, Sophie Austermeier, Beatriz Cristóvão, Gianluca Vascelli, Teresa Zelante and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. The unique Efg1 fungal virulence regulon in the catheterized bladder environment.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Phenotypic and genotypic analysis ofInfection and immunity · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Photodynamic Therapy Modulates pri-miRNA Expression inCurrent issues in molecular biology · 2025
    Article
  8. Article
  9. Antifungal Activities of Multi-Halogenated Indoles Against Drug-ResistantInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sophia U J Hitzler *Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany.ORCID http://orcid.org/0000-0002-3582-2544
Candela Fernández-Fernández *Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany.ORCID http://orcid.org/0000-0002-3277-7522
Kerstin GüntherDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Jena, Germany.ORCID http://orcid.org/0000-0001-8230-5972
Axel DietschmannJunior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany.ORCID http://orcid.org/0000-0002-0598-9714
Hrant HovhannisyanLife Sciences Department, Barcelona Supercomputing Center (BSC-CNS), Barcelona, Spain.ORCID http://orcid.org/0000-0003-2627-8505
Anna MöslingerDepartment of Microbial Pathogenicity Mechanisms, Leibniz-HKI, Jena, Germany.ORCID http://orcid.org/0009-0008-2741-2714
Sophie AustermeierDepartment of Microbial Pathogenicity Mechanisms, Leibniz-HKI, Jena, Germany.ORCID http://orcid.org/0000-0002-1048-5983
Beatriz CristóvãoJunior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany.
Gianluca VascelliDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Teresa ZelanteDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID http://orcid.org/0000-0002-7071-0302
Marina PekmezovićJunior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany.
Bernardo Ramírez-ZavalaInstitute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-8063-9255
Joachim MorschhäuserInstitute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0003-4227-8687
Oliver WerzDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Jena, Germany.ORCID http://orcid.org/0000-0002-5064-4379
Toni GabaldónLife Sciences Department, Barcelona Supercomputing Center (BSC-CNS), Barcelona, Spain.
Paul M JordanDepartment of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Jena, Germany.ORCID http://orcid.org/0000-0002-8364-4236
Slavena VylkovaSeptomics Research Center, Friedrich Schiller University, and Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.
Mark S GresnigtJunior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans-Knöll-Institute (Leibniz-HKI), Jena, Germany. mark.gresnigt@leibniz-hki.de.ORCID http://orcid.org/0000-0002-9514-4634

Funding

Boehringer Ingelheim Stiftung (Boehringer Ingelheim Foundation) Exploration GrantBundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) BMBF 03Z22JN11Carl-Zeiss-Stiftung (Carl Zeiss Foundation) Jena School of Microbial Communication PhD extension grantDeutsche Forschungsgemeinschaft (German Research Foundation) CRR/TRR124 FungiNet A7 210879364Deutsche Forschungsgemeinschaft (German Research Foundation) CRR/TRR124 FungiNet C1 210879364Deutsche Forschungsgemeinschaft (German Research Foundation) CRR/TRR124 FungiNet C2 210879364Deutsche Forschungsgemeinschaft (German Research Foundation) project no. 434385622 / GR 5617/1-1EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 847507 (HDM-FUN)Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) project number S006424N DeVEnIR
6 · The paper itself

Abstract

Pathogenicity mechanisms of the yeast Candida albicans involve filamentous growth, adhesion, invasion, and toxin production. Interestingly, clinical isolates, and other Candida spp., can cause infection independent of filamentation or toxin production. These strains and species often are characterized as avirulent ex vivo, yet this does not correlate with their potential to cause infection. We hypothesized that specific host factors, which trigger pathogenicity in vivo, are absent in in vitro infection models and thereby clinical isolates can seem avirulent ex vivo. We investigated how albumin, the most abundant protein in humans, impacts infection and cytotoxic potential of C. albicans in vitro. The presence of albumin induces otherwise non-damaging and non-filamentous clinical isolates to cause host cell cytotoxicity. Moreover, avirulent deletion mutants deficient in filamentation, adhesion, or toxin production are restored in their cytotoxicity by albumin. This involves transcriptional and metabolic reprogramming of C. albicans, increasing biofilm formation and production of the oxylipin 13-hydroxyoctadecadienoic acid, driving host cell cytotoxicity. Collectively, our study uncoveres a pathogenicity mechanism by which C. albicans causes epithelial cytotoxicity independent of its conventional virulence mechanisms. This alternative pathogenicity strategy helps to explain the avirulence of clinical isolates ex vivo, when they are separated from the host environment.

Indexed as

AlbuminsCandida albicansCandidiasisBiofilmsFungal ProteinsGene Expression Regulation, FungalHost-Pathogen InteractionsHumansVirulenceAlbuminsFungal Proteins

Identifiers

PMID40646002
PMCPMC12254302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.